Citations

Clear

362 citation(s) found for "Shaw, D A".

New Definition for Postoperative Spine Infection (PSI)
Shaw, Jeremy D. , Nelson, Sandra B. , Simpfendorfer, Claus, Berbari, Elie F. , Henry, Michael , Kleck, Christopher J. , Savage, Jason, Agarwal, Nitin, Oyekan, Anthony A. , Rodrigues-Pinto, Ricardo, Wouthuyzen-Bakker, M., Agarwal, Nitin , Rodrigues‐Pinto, Ricardo , Wouthuyzen‐Bakker, Marjan , Tande, Aaron J.

Mayo Clinic

Spine | December 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/brs.0000000000005604 | PMID 41432018 Get It

Study Design. Modified Delphi consensus process Objective. To establish a standardized, consensus-driven definition for postoperative spine infection (PSI) for research, diagnosis, and management. Summary of Background Data. Postoperative infection is a devastating and common complication following spine surgery. Rates of PSI in the literature range from 0% to over 20% depending on surgical indication and invasiveness. Despite the implications of PSI, there is no universally accepted diagnostic standard or consensus definition for infection following spine surgery, hindering research and treatment of this challenging clinical condition. Methods. A multispecialty workgroup convened by the Musculoskeletal Infection Society (MSIS) conducted a systematic literature review. Using data from the systematic review, an expert panel completed a modified Delphi process to achieve consensus. The panel included nine fellowship-trained, board-certified physicians with expertise in infectious diseases, orthopaedic and neurologic spine surgery, and musculoskeletal radiology. Iterative rounds focused on criterion selection, importance ranking, categorical grouping, and final constellation development for PSI diagnosis. Consensus was defined as a 2/3 majority, with a target of 100%. Results. The workgroup achieved 100% consensus on a new PSI definition, which incorporates six clinical domains: wound features, microbiology, imaging, inflammatory biomarkers, intraoperative findings, and histology. A single microbiological stand-alone criterion—identification of a phenotypically indistinguishable organism from two or more deep operative site specimens—was established as pathognomonic for postoperative spine infection. Additional primary and secondary supporting criteria were defined, with specific combinations required to classify cases as definite or probable PSI. Final definitions were ratified by the boards of MSIS and the European Bone & Joint Infection Society (EBJIS) Conclusion. This consensus-based definition provides a standardized framework for diagnosing postoperative spine infection, facilitating research and clinical management. The criteria balance sensitivity and specificity across diverse clinical scenarios and represent the first multispecialty, society-endorsed definition for PSI.
AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning
Corraes, Andre De Menezes Silva , Shaw, Monica , Holmes, Lucy , Burgstahler, Allison, Riester, Kimberly, Jankowski, Matthew, Hampel, Paul J. , Kapoor, Prashant , Khurana, Arushi , Kourelis, Taxiarchis , Leung, Nelson , Warsame, Rahma , Kumar, Shaji , Ansell, Stephen M. , Johnston, Patrick B. , Guzman, Emmanuel Contreras , Shaw, Monica, Holmes, Lucy, Burgstahler, Allison, Mclean, Jody, Villasboas, José C. , Bennani, N. Nora , Binder, Moritz , Gertz, Morie A. , Kenderian, Saad S. , Cook, Joselle , Shah, Meera , Alkhateeb, Hassan B. , Wang, Yucai , Durani, Urshila , Paludo, Jonas , Lin, Yi

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6131-6131

10.1182/blood-2025-6131 Get It

Abstract Introduction: CAR-T therapy has transformed cancer therapy. with its first Food and Drug Administration (FDA) approved product in August 2017. Given the expanding indications and growing experience, particularly with management of immediate toxicities requiring specialized expertise such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity syndrome (ICANS), FDA recently removed the Risk Evaluation and Mitigation Strategies (REMS) for CD19 and BCMA targeting CAR-T on June 26th2025. In particular, given that CRS and ICANS typically occur in the first 2 weeks post CAR-T infusion, the minimum required stay near CAR-T treatment center is reduced from one month to 2 weeks. While this could reduce treatment burden for patients (pts) who need to travel away from home to receive CAR-T, there is a need to update the transition of care from CAR-T center to pts' local oncology practice. Pts carry in their rate of recovery and have varying supportive care needs in the second half of the month post CAR-T infusion. To assist with care transition and planning, we examine the use of AI multimodal large language model (LLM) to predict patients' supportive care needs 2 weeks after CAR-T infusion based on the clinical data at the time of CAR-T evaluation, prior to leukapheresis. This timepoint was selected to also maximize travel, lodging and caregiver planning for pts and family as well. Methodology: Pts who were treated with FDA-approved CAR-T at Mayo Clinic Rochester between December 2022 and June 2025 were examined. Based on experiences with referral practices in the Midwest region, we defined patients with high monitoring needs as those who between day 14-30 post CAR-T had either hospital admission due to recurrent CRS or ICANS or required transfusion of more than 1 blood product per week (red blood cell or platelets). Others were classified as low monitoring needs. Clinical notes, labs, vital signs and electrocardiogram at the time of CAR-T evaluation were abstracted and summarized by Gemini LLM for association with patients with high versus low monitoring needs post CAR-T. Model was developed and tested for predicted needs and concordance with actual outcome of these pts. Results: Among the 362 pts who received FDA approved CAR-T in the timeframe, 84 pts had high monitoring needs. An additional 84 pts with low monitoring needs were randomly selected from 278 pts. These were divided into a training cohort and test cohort of 84 pts each, with 42 pts with high and 42 pts with low monitoring needs. Demographics of the two cohorts displayed no statistical difference. LLM analysis of the clinical data at the time of CAR-T eval identified 5 categories associated with risk for high monitoring needs: 1) Disease status (clinical notes about bulky, progressive disease or CNS involvement); 2) inflammatory and tumor burden markers (CRP, LDH); 3) hematologic status (platelet, plt; neutrophil count ANC); 4) renal function; 5) performance status. Using common clinical lab parameter convention (platelets <100, ANC< 1, CrCl< 30ml/min), and prioritizing for not missing pts with high monitoring needs, LLM model was defined to predict patients for high monitoring needs if high risk feature was identified in category 1 or any category combinations; whereas patients with no high risk feature or only 1 category that is not disease status was predicted as low monitoring needs. In this model, the sensitivity was 85.7%, specificity 23.8%, F1 score 65.5%. Applying this model to test cohort 2, the sensitivity was 83.3%, specificity 28.6%, and F1 score 65.4%. Discussion: We demonstrate proof-of-concept that LLM can be used to analyze clinical data at the time of evaluation for CAR-T eligibility to predict for supportive care needs post treatment. Not surprisingly, features identified by LLM to be associated with high monitoring needs are those previously reported by us and others at the time of CAR-T evaluation and or pre-lymphodepletion to be associated with risk for cytopenia, infection, hospitalization and non-relapse mortality. Based on the summary output generated by LLM, additional opportunities for classification methods were identified to improve specificity and balanced accuracy of the LLM model. This is a promising tool for further development to assist clinicians and patients to plan their treatment journey.
Large language model for abstraction of CAR-T therapy toxicities data
Joseph, Kayla, Corraes, Andre De Menezes Silva, Guzman, Emmanuel Contreras, Tan, Melinda, Shaw, Monica, Mclean, Jody, Riester, Kimberly, Jankowski, Matthew, Bruno, Ramona, Holmes, Lucy, Burgstahler, Allison, Bennani, N. Nora, Gertz, Morie, Hampel, Paul, Kapoor, Prashant, Kenderian, Saad, Khurana, Arushi, Kourelis, Taxiarchis, Leung, Nelson, Shah, Mithun, Warsame, Rahma, Durani, Urshila, Kumar, Shaji, Ansell, Stephen, Alkhateeb, Hassan, Hathcock, Matthew, Wang, Yucai, Johnston, Patrick, Paludo, Jonas, Lin, Yi, Joseph, Kayla, Corraes, Andre De Menezes Silva, Guzman, Emmanuel Contreras, Tan, Melinda, Shaw, Monica, Mclean, Jody, Riester, Kimberly, Jankowski, Matthew, Bruno, Ramona, Holmes, Lucy, Burgstahler, Allison, Bennani, N. Nora, Gertz, Morie, Hampel, Paul, Kapoor, Prashant, Kenderian, Saad, Khurana, Arushi, Kourelis, Taxiarchis, Leung, Nelson, Shah, Mithun, Warsame, Rahma, Durani, Urshila, Kumar, Shaji, Ansell, Stephen, Alkhateeb, Hassan, Hathcock, Matthew, Wang, Yucai, Johnston, Patrick, Paludo, Jonas, Lin, Yi

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6139-6139

10.1182/blood-2025-6139 Get It

Abstract Introduction: Reporting patient outcomes by CAR-T treatment centers is part of the accreditation requirement under the FACT (Foundation for Accreditation of Cell Therapy) Immune Effector Cell (IEC) Program standard. Currently, this is a time-consuming and manual process, making it increasingly difficult to sustain with the growing CAR-T applications and patient volume. The objective of this study is to evaluate how a Large Language Model (LLM) can be used to automate the abstraction and summarization of medical record for CAR-T toxicities. Methods: Clinical data from patients treated with CAR-T between January 2018 and June 2025, including hematology clinical notes, lab results, flowsheets, vital signs, and medication administration record, were used as the source of patient information. The American Society of Transplant and Cell Therapy (ASTCT) CAR-T toxicity grading guideline for cytokine release syndrome (CRS) and immune effector cell associated neurologic syndrome (ICANS) were used to define these toxicities. With the large context window of the LLM (Gemini 2.5 pro), we created a prompt by embedding both the patient data and the ASTCT guidelines for CRS and ICANS, along with an outline of specific information we aimed to abstract from the data. Additionally, the LLM was instructed to provide contextual justification for the data it extracted from patient information. The LLM-generated output included event onset date, resolution date, maximum grade, date of maximum grade, and medications given for management. The CRS and ICANS outcome reports generated by the LLM were then compared to the IEC compliance program data. Any discrepancies identified were reviewed manually. Results: Among patients (pt) treated with CAR-T in the specified timeframe, 47 were selected as training cohort. This cohort included pt with toxicities events, no events, and a mix of events of varying grades. For the test cohort, 66 pts who received CAR-T from March to June 2025 were included. Demographics for the training and test cohorts are reflective of evolving clinical practice (training, test cohorts: median age 69, 65; male 55%, 74%; lymphoma/leukemia 66%, 48%; multiple myeloma 34%, 52%; CD19 CAR-T 46%, 50%). Compared to data from the IEC compliance program, the LLM-generated summaries for CRS events demonstrated an accuracy of 90%, precision 95%, sensitivity 100%, specificity 80%, F1 score 97%, and Matthew's correlation coefficient 87%. For ICANS event, the LLM achieved an accuracy of 91%, precision 92%, sensitivity 92%, specificity 90%, F1 score 92%, Matthew's correlation coefficient 83%. Maximum grade, for both CRS and ICANS, were identified with >90% accuracy. However, dates for CRS and ICANS were less accurate, with the lowest accuracy noted in identifying the event resolution date, 45% for CRS and 67% for ICANS. Medical records were reviewed for all discrepancies between the LLM and the IEC Compliance Program data. The most common discrepancy was a mismatch in event resolution date, determined to be due to differing criteria used by the compliance team and the LLM prompt. Of note, a few discrepancies were attributed to missed information by the IEC Compliance Team, which was correctly identified and categorised by the LLM. An updated LLM prompt (LLMv2) was developed and applied to the test cohort. In version 2, the prompt was revised to include clearer instructions on how to summarize CRS and ICANS events, as well as new instructions on additional data elements to be summarized. The performance of LLMv2 on this cohort for CRS event identification was 100% across all categories (accuracy, precision, sensitivity, specificity, F1 score, and Matthew's correlation coefficient). For ICANS the LLMv2 achieved accuracy of 96%, precision 69%, sensitivity 100%, specificity 93%, F1 score 82%, Matthew's correlation coefficient 80%. Accuracy in identifying event resolution date improved significantly from 64% to 99%. Conclusions: Our study demonstrates that LLMs can significantly reduce the time required to abstract and summarize CAR-T toxicities, while maintaining high accuracy. One limitation of our study is that it is based on data from a single institution. However, plans are already underway to evaluate the use of LLMs in a multi-institutional setting.
Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study
Bo‐Subait, Stephanie, Logan, Brent R. , Leckrone, Erin , Smith, Sarah , Stefanski, Heather, Malmberg, Craig, Modi, Dipenkumar , Meade, Javier Bolaños, Rao, Uttam K. , Milner, Jordan , Jamieson, Katarzyna , Carrum, George, Kosuri, Satyajit, Cook, Rachel J. , Ballen, Karen K. , Loren, Alison W. , Arai, Sally , Choi, Sung Won , Shaw, Bronwen E. , Larkin, Karilyn , Gooptu, Mahasweta , Malki, Monzr M. Al , Auletta, Jeffery J. , Spellman, Stephen R. , Askar, Medhat , Cusatis, Rachel , Khimani, Farhad , Hamadani, Mehdi , Maiers, Martin , Stanek, Joseph , Abboud, Ramzi , Dholaria, Bhagirathbhai , Hogan, William J. , Reshef, Ran , Qayed, Muna , Broglie, Larisa , Devine, Steven M. , Jiménez, Antonio , Shaffer, Brian C.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4232-4232

10.1182/blood-2025-4232 Get It

Abstract Allogeneic hematopoietic cell transplantation (HCT) using an HLA mismatched unrelated donor (MMUD) with calcineurin inhibitor-based graft versus host disease (GVHD) prophylaxis results in increased incidence of non-relapse mortality (NRM) and lower survival compared to matched donor HCT. The NMDP sponsored 15-MMUD study demonstrated that post-transplant cyclophosphamide (PTCy)-based prophylaxis following bone marrow derived MMUD HCT resulted in reduced incidence of GVHD and favorable survival. Because marrow grafts can be difficult to procure and vary in quality, we conducted a phase II, prospective, multicenter study to evaluate PTCy-based GVHD prophylaxis in adult recipients of MMUD using peripheral blood stem cell (PBSC) allografts. The primary study aim was to estimate the probability of one-year overall survival (OS) post HCT. Secondary aims were to assess other key clinical endpoints and determine the rate of severe infections. Initial results of the first 70 recipients who received reduced intensity conditioning (RIC) were previously reported by Al Malki et al (JCO 2025) demonstrating a 1-year OS of 78.6% (95% CI, 67% to 86.5%). Here, we report results from a planned expansion of the study that included 123 additional RIC recipients, with updated results from the initial cohort of 70 patients (total N = 193 subjects) treated at 33 centers. Study participants received cyclophosphamide 50 mg/kg (ideal body weight) administered on days 3 and 4 post HCT with tacrolimus and mycophenolate mofetil as previously described (Al Malki, JCO, 2025). The median study participant age was 65.0 (range: 22.9-78.9); 92 (47.7%) of participants were male, and 84 (43.5%) identified as having other than non-Hispanic white ancestry. The HCT comorbidity index was high-risk (>3) in 65 (33.7%). Underlying histologic diagnosis was AML in 96 (49.7%) participants, MDS in 43 (22.3%), ALL in 20 (10.4%), lymphoma or CLL in 24 (12.4%), and CML/other leukemias in 10 (5.2%). Conditioning regimens used were fludarabine and melphalan (100 or 140 mg/m2) (N=120; 62.2%), 2-day busulfan and fludarabine (N=38; 19.7%), and fludarabine, cyclophosphamide and total body irradiation (200 cGy) (N=32; 16.6%). Donor HLA matching (considering HLA-A, -B, -C, and -DRB1) was 7/8 in 131 (67.9%) of participants, 6/8-matched in 51 (26.4%), and 4-5/8-matched in 11 (5.7%) participants. Median donor age was 25.5 years (range: 18.7-35.7). The one-year overall OS estimate was 79.6% (95% confidence interval [CI]: 73.2-84.7). Survival was similar among HLA 7/8-matched donor recipients (77.8%, 69.7-84%) and <7/8 matched donor recipients (83.7%, 71.8-90.9%). The one-year GVHD-free, relapse-free survival (GRFS) was 49.9% (42.6-56.9%) and the one-year progression-free survival was 70.2% (63.2-76.2%). The one-year cumulative incidence (CI) rates of NRM and relapse were 12.5% (8.3-17.6%) and 17.3%(12.3-23%), respectively. The 6-month CI of grade II-IV and grade III-IV acute GVHD were 40.0% (33.0-46.8%) and 7.8% (4.6-12.1%), respectively. The one-year incidence of all chronic GVHD and severe chronic GVHD were 15.6% (10.7-21.2%) and 3.7% (1.6-7%), respectively, by NIH consensus criteria. The CI of grade 1-4 cytokine release syndrome (CRS) by day 7 post HCT was 28.0% (21.8-34.9%), and grade 3-4 CRS was 0.5% (0-2.9%). Primary engraftment failure occurred in 9 (4.7%) participants. Among 145 evaluated participants, 85.5% were >95% donor in blood chimerism at day 100 post HCT. Within the first 100 days after HCT, CTCAE grade 2-5 infections occurred in 113 (58.5%) of participants and grade 3-5 infections occurred in 59 (30.6%) of participants. The most common etiologies of grade 2-5 infections were bacterial (N=78), followed by viral (N=48). The most common grade 3-5 non-infectious toxicities were cardiac disorders, which occurred in 4 (2.1%) of participants. In conclusion, the results including this expansion cohort demonstrate encouraging 1-year OS, NRM and relapse rates in RIC recipients of PTCy-based GVHD prophylaxis and PBSC allografts from MMUDs. This larger cohort of 193 recipients re-affirm the results from the initial cohort with greater robustness.Measures to mitigate infection risk are likely to further improve outcomes. Reducing the dose of PTCy is a candidate approach currently being tested in the ongoing OPTIMIZE trial (NCT 06001385).These results support the extension of PBSC MMUD using PTCy to individuals who lack an HLA-matched donor and require RIC HCT.
Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study
Bo‐Subait, Stephanie, Logan, Brent R. , Smith, Sarah , Leckrone, Erin , Stefanski, Heather, Malmberg, Craig, Modi, Dipenkumar , Meade, Javier Bolaños, Rao, Uttam K. , Milner, Jordan , Jamieson, Katarzyna , Carrum, George, Kosuri, Satyajit, Cook, Rachel J. , Ballen, Karen K. , Loren, Alison W. , Arai, Sally , Choi, Sung Won , Shaw, Bronwen E. , Larkin, Karilyn , Malki, Monzr M. Al , Auletta, Jeffery J. , Spellman, Stephen R. , Askar, Medhat , Cusatis, Rachel , Shaffer, Brian C. , Khimani, Farhad , Gooptu, Mahasweta , Hamadani, Mehdi , Maiers, Martin , Stanek, Joseph , Abboud, Ramzi , Dholaria, Bhagirathbhai , Hogan, William J. , Reshef, Ran , Qayed, Muna , Broglie, Larisa , Devine, Steven M. , Jiménez, Antonio

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 936-936

10.1182/blood-2025-936 Get It

Abstract Allogeneic hematopoietic cell transplantation (HCT) remains inaccessible to many patients, particularly those of non-European ancestry, due to the limited availability of matched unrelated donors (URD). While single-HLA mismatched donors (7/8) often yield acceptable outcomes, URD HCT mismatched at ≥ 2 HLA alleles (<7/8) has historically been associated with poor survival and prohibitive toxicity. Post-transplant cyclophosphamide (PTCy) has improved outcomes following mismatched unrelated donor (MMUD) HCT, potentially enabling less stringent donor matching. Whether the degree of donor-recipient HLA disparity remains prognostic after MMUD HCT when PTCy is used is unknown. The ACCESS trial (NCT04904588) was conducted by the Center for International Blood and Marrow Transplant Research Clinical Research Organization and prospectively evaluated PTCy-based graft versus host disease (GVHD) prophylaxis in adult recipients of 4–7/8 (HLA-A, -B, -C and -DRB1) MMUD peripheral blood stem cells (PBSC) from donors age ≤35 years old following either myeloablative (MAC) or reduced intensity/non-myeloablative (RIC/NMA) conditioning. This analysis focused on all adult recipients of <7/8 grafts enrolled on the study across both conditioning strata, with descriptive comparison to patients who received 7/8 MMUD PBSC grafts. The primary endpoint was 1-year overall survival (OS). Secondary endpoints included primary graft failure (PGF), non-relapse mortality (NRM), relapse, acute and chronic GVHD, and GVHD-free relapse-free survival (GRFS). A total of 268 adults received MMUD PBSC grafts: 85 with <7/8 matches (MAC: n=23; RIC/NMA: n=62) and 183 with 7/8 matches (MAC: n=52; RIC/NMA: n=131). Among <7/8 recipients, median age was 57 years old (range, 24–78), 49% were male, with diagnoses of acute myeloid leukemia (AML) (55%), myelodysplastic syndromes (MDS) (15%), and lymphoma (14%). HLA mismatch distribution in the <7/8 group was 6/8 in 82%, 5/8 in 14%, and 4/8 in 4%. Most received fludarabine/melphalan (44%) or myeloablative busulfan/fludarabine (21%). Median CD34+ cell dose was 5.5 ×10^6/recipient kg (range: 3.2-8.0) and 75% of grafts were cryopreserved prior to infusion. Median donor age was 25.8 (range: 18.7-35.7) in the 7/8 group and 25.0 (range: 18.3-34.8) in the <7/8 group. The <7/8 cohort was racially and ethnically diverse, with 61% identifying as other than non-Hispanic white. The 7/8 cohort had a median age of 63 years old (range, 20–79), with 52% male. Disease distribution, conditioning intensity, and infused cell doses were similar to the <7/8 group. A smaller proportion of grafts were cryopreserved (61%), and 47% of patients identified as other than non-Hispanic White. One-year OS for <7/8 recipients was 86% (95% CI: 76–92%), compared to 79% (95% CI: 72–84%) in 7/8 recipients. One-year incidence of relapse was 23% (95% CI: 14–33%) in the <7/8 group and 17% (95% CI: 12–23%) in 7/8 recipients; NRM was 8% (95% CI: 4–16%) and 14% (95% CI: 9–19%), respectively. GRFS was 55% (95% CI: 43–65%) for <7/8 and 51% (95% CI: 44–58%) for 7/8 recipients. PGF occurred in 8% (95% CI: 3–18%) of <7/8 RIC recipients and 3% (95% CI: 1–8%) of 7/8 RIC recipients; no MAC recipients had PGF. At 6 months post-HCT, grade II–IV acute GVHD occurred in 34% (95% CI: 24–44%) of <7/8 patients and 39% (95% CI: 32–46%) of 7/8; grade III–IV acute GVHD was observed in 7% (95% CI: 3–14%) and 8% (95% CI: 5–13%), respectively. Moderate to severe chronic GVHD (NIH consensus criteria) at one year occurred in 8% (95% CI: 3–15%) of <7/8 recipients and 11% (95% CI: 7–16%) of 7/8 recipients. When grouped by conditioning intensity, 1-year outcomes within the <7/8 cohort were: OS 91% after MAC and 84% after RIC/NMA; relapse in 32% after MAC and 20% after RIC/NMA, respectively; GRFS was 53% for MAC and 55% for RIC/NMA; and NRM remained low at 9% after MAC and 8% after RIC/NMA. In this cohort of adult recipients of <7/8 MMUD PBSC grafts with PTCy-based GVHD prophylaxis enrolled on the ACCESS study, 1-year OS exceeded 80% and was comparable to 7/8 recipients. Relapse, NRM, and GVHD rates were similarly favorable and consistent with outcomes reported in 7/8 donor recipients. These findings support extending suitable MMUD match considerations to include 4-6/8 in the context of PTCy, potentially enabling near-universal donor access, while allowing for optimization of other non-HLA donor factors.
Single-cell transcriptomic analysis reveals T cell heterogeneity and metabolic reprogramming in human immune-mediated glomerulonephritis
Qing, Jianbo , Zhao, Yiting , Cheungpasitporn, Wisit, Miao, Jing , Wu, Henglan , Wu, Junnan , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Miao, Jing , Thongprayoon, Charat

Mayo Clinic

Autoimmunity | November 16, 2025 | Volume: 58 | Issue: 1 | Pages: No page available

10.1080/08916934.2025.2582720 | PMID 41241792 Get It

Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, Linda S. , Mahinrad, Simin , Edelmayer, Rebecca M. , Potter, William Z. , Hutten, Samantha J. , Anticevic, Alan , Taylor‐Burds, Carol , Winston, Charisse N. , Coetzee, Timothy , Paulsen, Jane S. , Mantua, Valentina, Childers, Eva P. , Jack, Clifford R. , Jagust, William J. , Wagner, John A. , Sivakumaran, Sudhir , Shaw, Leslie M. , Jack, Clifford R , Jagust, William J , Wagner, John A , Sivakumaran, Sudhir , Shaw, Leslie , Mahinrad, Simin , Kolb, Hartmuth C. , Sharma, Vikas Mohan

Mayo Clinic

Science Translational Medicine | November 5, 2025 | Volume: 17 | Issue: 823 | Pages: No page available

10.1126/scitranslmed.adr2511 | PMID 41191776 Get It

Decades of research on biomarker identification and integration in Alzheimer’s disease (AD) have helped to advance biologically driven disease models, disease subtypes, and disease-modifying treatments. Key lessons learned from AD biomarker development include the need for integration of new biological insights, investment in large cross-sectional and longitudinal studies, a multicomponent biomarker approach, and recruitment of clinical trial cohorts and biosamples that are representative of the target population. We describe how these lessons are being applied in Parkinson’s disease, Huntington’s disease, multiple sclerosis, and psychotic disorders as use cases to inform biomarker-based approaches across central nervous system disorders.
POSTOPERATIVE SPINAL INFECTIONS: THE CHALLENGE OF INCONSISTENT DEFINITIONS AND THE PATH TOWARDS CONSENSUS
Alavi, Amin Seyed Mohammad, Gori, Andrea , Shaw, Jeremy D. , Berbari, Elie F. , Petri, Francesco , Borgonovo, Fabio , Alavi, Amin Seyed Mohammad, Matsuo, Takahiro , Tande, Aaron J.

Mayo Clinic

Orthopaedic Proceedings | November 4, 2025 | Volume: 107-B | Issue: SUPP_12 | Pages: 53-53

10.1302/1358-992x.2025.12.053 Get It

Background The rising number of spinal surgeries has been paralleled by an increase in postoperative spine infections (PSIs), now identified as the third most common surgical complication. The absence of a standardized PSI definition complicates clinical management and research. This meta-epidemiological study was conducted to establish clear diagnostic criteria to aid clinicians and researchers in consistently identifying and reporting PSIs. Methods In accordance with PRISMA guidelines, a comprehensive literature search was performed using Ovid MEDLINE on March 14, 2024, by a medical librarian. Studies were considered eligible if they reported clear diagnostic definitions of PSI in at least ten adult patients. The primary objective was to review existing PSI diagnostic criteria and classify them into thematic clusters. We developed standardized diagnostic combinations based on 13 predefined criteria sourced from clinical practice guidelines and previous research (see Table 1). Results From an initial pool of 1,466 studies, 101 were included. The vast majority were retrospective (91/101, 92.1%), with most studies (77/101, 76.2%) utilizing established criteria, such as those from the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) or the CDC. Seven studies combined these predefined criteria with additional detailed descriptions. Among studies using independent definitions, clinical signs and symptoms were the most commonly reported criteria (13/24, 54.2). The criteria were grouped into clinical, microbiological, and radiological categories, with most studies employing clinical criteria either alone or alongside microbiological or imaging findings (Figure 1). Conclusion These findings highlight the urgent need for a standardized definition of PSI that integrates clinical, microbiological, and radiological elements. Implementing such a unified diagnostic framework could enhance accuracy, address limitations related to hardware complications, wound drainage interpretation, and imaging ambiguities, and improve current surveillance practices. For any figures or tables, please contact the authors directly.
Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Rohrberg, Kristoffer Staal , Lopez, Juanita , Milhem, Mohammed , Blank, Christian U. , Reijers, Irene L. M. , Plummer, Ruth , Piha‐Paul, Sarina A. , Jänne, Pasi A. , Shaw, Heather M. , Debruyne, Philip R. , Lao, Cristopher , Gort, Eelke , Zhao, Yujie , Schöffski, Patrick , Chen, Andrew William , Cohen, Eric A. , Katz, Sharyn I. , Brady, Luther W. , Qutaish, Mohammed , Castro, Patricia Garrido , Pencheva, Nora , Fu, Yali , Windfeld, Kristian , Reiter, Panagiota , Amiri, Katayoun I. , Ahmadi, Tahamtan , Forssmann, Ulf , Vergote, Ignace , Lopez, Juanita S , Milhem, Mohammed M , Reijers, Irene , Thistlethwaite, Fiona , Plummer, Ruth , Piha-Paul, Sarina A , Jänne, Pasi A , Shum, Elaine , Shaw, Heather M , Debruyne, Philip R , Lao, Cristopher , Baurain, Jean-Francois , Choe, Jennifer H , Gort, Eelke , Zhao, Yujie , Jerusalem, Guy , Schöffski, Patrick , Chen, Andrew William , Cohen, Eric A , Mankowski, Walter C , Roshkovan, Leonid , Katz, Sharyn I , Kontos, Despina , Brady, Lauren K , Qutaish, Mohammed , Castro, Patricia Garrido , Pencheva, Nora , Bajaj, Gaurav , Fu, Yali , Windfeld, Kristian , Reiter, Panagiota , Jure-Kunkel, Maria , Higgs, Brandon W , Amiri, Katayoun I , Ahmadi, Tahamtan , Forssmann, Ulf , Ramalingam, Suresh S. , Vergote, Ignace , Baurain, Jean‐François , Jérusalem, Guy , Mankowski, Walter C.

Mayo Clinic

Cancer Research Communications | October 30, 2025 | Volume: 5 | Issue: 11 | Pages: 2066-2078

10.1158/2767-9764.crc-25-0359 | PMID 41166388 Get It

Abstract Purpose: AXL, a receptor tyrosine kinase related to oncogenic processes, is aberrantly expressed in various cancers and associated with treatment resistance. Enapotamab vedotin (EnaV), a novel anti-AXL human IgG1 and monomethyl auristatin E antibody–drug conjugate, demonstrated antitumor activity in preclinical models, including non–small cell lung cancer (NSCLC). This phase 1/2 study assessed the safety and preliminary efficacy of EnaV in solid tumors. Patients and Methods: This study comprised dose-escalation and dose-expansion phases; both phases investigated EnaV once every 3 weeks (Q3W) and EnaV on days 1, 8, and 15 of a 28-day cycle (3Q4W). Primary objectives determined the maximum tolerated dose (dose escalation) and safety (dose expansion). Pharmacokinetic profile, antitumor activity, and AXL expression were also assessed. Results: During dose escalation, 32 patients received EnaV Q3W; 15 received EnaV 3Q4W. The maximum tolerated dose and recommended phase 2 dose were 2.2 mg/kg in Q3W and 1.0 mg/kg in 3Q4W schedules. In dose expansion, 189 patients received EnaV Q3W; 70 received EnaV 3Q4W. Common adverse events in dose expansion included fatigue, constipation, nausea, decreased appetite, and diarrhea. Overall response rates ranged from 4.5% to 12.5% with Q3W dose schedule and from 9.1% to 11.5% with 3Q4W dose schedule. Disease control rates for NSCLC cohorts were 40.9% to 50.0%. NSCLC subset analysis demonstrated correlation between radiomics signature and disease control. The relationship between clinical activity and AXL expression was not apparent. Conclusions: EnaV had an acceptable safety profile; however, because the evaluation of antitumor activity did not show clinically meaningful responses, clinical development of EnaV was discontinued. Significance: EnaV, an anti-AXL human IgG1 and monomethyl auristatin E antibody–drug conjugate, showed single-agent antitumor activity in preclinical models. This phase 1/2 study of EnaV demonstrated a manageable safety profile and antitumor activity in selected tumor types. Further studies exploring alternative targeting modalities, patient selection, and/or combinations are needed.
Using large language models to automate summarization of CT simulation orders in radiation oncology
Cao, Meiyun, Hu, S.X. , Sharp, Jason, Clouser, Edward , Lam, Louis, Ding, Xiaoning, Toesca, Diego Santos, Raulston, Brianne C, Lindholm, Wendy S., Patel, Samir H. , Vora, Sujay A., Wang, P. , Clouser, Edward Lee , Lam, Linda L, Wang, Peilong , Liu, Wei , Toesca, Diego A.S. , Hu, Shaw, Sharp, Jason, Holmes, Jason , Liu, Wei

Mayo Clinic

Journal of Applied Clinical Medical Physics | October 28, 2025 | Volume: 26 | Issue: 11 | Pages: No page available

10.1002/acm2.70310 | PMID 41144781 Get It

Abstract Background In the current clinical workflow of radiation oncology, therapists manually summarize the physician‐issued Computed Tomography (CT) simulation orders to prepare patients' CT simulations. This process increases the workload, introduces variability in documentation quality, and is prone to human errors. Purpose This study aims to address these challenges using a large language model (LLM) to automate the generation of summaries from the CT simulation orders and evaluate its performance. Methods A total of 607 CT simulation orders were collected from the Aria database at our institution. A locally hosted LLaMa 3.1 405B model, accessed via the Application Programming Interface (API) service, was used to extract keywords from the CT simulation orders and generate summaries. The downloaded CT simulation orders were categorized into seven groups based on treatment modalities and disease sites. For each group, a customized instruction prompt was developed collaboratively with therapists to guide the LLaMa 3.1 405B model in generating summaries. The ground truth for the corresponding summaries was manually derived by carefully reviewing each CT simulation order and subsequently verified by therapists. The accuracy of the LLM‐generated summaries was evaluated by therapists using the ground truth. Results Over 98% of the LLM‐generated summaries aligned with the ground truth in terms of accuracy. Our evaluations showed an improved consistency in format and enhanced readability from the LLM‐generated summaries compared to the corresponding therapist‐generated summaries. This automated approach demonstrated consistent performance across all groups, regardless of treatment modality or disease site. Conclusions This study demonstrated the high precision and consistency of the LLaMa 3.1 405B model in extracting keywords and summarizing CT simulation orders, suggesting that LLMs have great potential to assist in this task, reduce the workload of CT simulation therapists and improve radiation oncology workflow efficiency.